BUSINESS
Sumitomo Dainippon Transfers Marketing Rights to 3 Brands Including Inteban to Teikoku Seiyaku
Sumitomo Dainippon Pharma transferred the marketing rights to the anti-inflammatory agents Inteban (indomethacin) and Catlep (indomethacin) and the agent for occlusive treatment of skin diseases Drenison (fludroxycortide) to Teikoku Seiyaku effective July 1. In the case of Inteban, the manufacturing…
To read the full story
BUSINESS
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





